Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Equities researchers at Leerink Partnrs issued their FY2027 EPS estimates for Lexeo Therapeutics in a report issued on Tuesday, April 23rd. Leerink Partnrs analyst M. Foroohar forecasts that the company will earn ($2.58) per share for the year. The consensus estimate for Lexeo Therapeutics' current full-year earnings is ($3.03) per share. Leerink Partnrs also issued estimates for Lexeo Therapeutics' FY2028 earnings at $0.12 EPS.
Lexeo Therapeutics Price Performance
LXEO stock traded down $0.34 during mid-day trading on Thursday, reaching $12.16. 51,316 shares of the stock traded hands, compared to its average volume of 102,934. The company has a current ratio of 7.21, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. Lexeo Therapeutics has a 52-week low of $9.00 and a 52-week high of $22.33. The stock has a fifty day moving average of $14.43.
Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last posted its quarterly earnings data on Monday, March 11th. The company reported ($0.86) EPS for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.15).
Hedge Funds Weigh In On Lexeo Therapeutics
A number of large investors have recently made changes to their positions in LXEO. Eventide Asset Management LLC acquired a new position in shares of Lexeo Therapeutics in the 4th quarter valued at about $40,298,000. Omega Fund Management LLC acquired a new position in shares of Lexeo Therapeutics in the 4th quarter valued at about $28,955,000. Finally, Blackstone Inc. acquired a new position in shares of Lexeo Therapeutics in the 4th quarter valued at about $9,342,000. Institutional investors and hedge funds own 60.67% of the company's stock.
Lexeo Therapeutics Company Profile
(
Get Free Report)
Lexeo Therapeutics, Inc operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations.
See Also
Before you consider Lexeo Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lexeo Therapeutics wasn't on the list.
While Lexeo Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
